Targeting KRAS‐mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2

Targeting KRAS‐mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2

The Kirsten rat sarcoma (KRAS) oncogene was considered “undruggable” until the development of sotorasib, a KRASG12C selective inhibitor that shows favorable effects against lung cancers. MRTX1133, a novel KRASG12D inhibitor, has shown promising results in basic research, although its effects against...

Full description

Saved in:
Bibliographic Details
Main Authors: Satoru Miyazaki, Masato Kitazawa, Satoshi Nakamura, Makoto Koyama, Yuta Yamamoto, Nao Hondo, Masahiro Kataoka, Hirokazu Tanaka, Michiko Takeoka, Daisuke Komatsu, Yuji Soejima
Format: Article
Language:English
Published: Wiley 2025-02-01
Series:Molecular Oncology
Subjects:
fedratinib
KRAS
MRTX1133
pancreatic cancer
sotorasib
trametinib
Online Access:https://doi.org/10.1002/1878-0261.13751
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/1878-0261.13751

Similar Items